Key result
The biological activity of daunorubicin derivatives against mouse P388 tumors is directly proportional to RNA polymerase inhibition and inversely proportional to DNA complex dissociation rate.
In vitro techniques measuring RNA polymerase inhibition and DNA complex dissociation rate can estimate the in vivo biological efficacy of daunorubicin derivatives.
Answers are grounded in this paper and cite their sources.
May prioritize daunorubicin derivatives in preclinical screens; hypothesis-generating and should not yet inform clinical use.
The synthesis of potentially specific antitumor peptide derivatives of daunorubicin is presented. The interaction specificites of the drugs with nucleic acids have been examined via stop-flow kinetics as well as the inhibition of DNA template activity. It is found that the biological activity of the daunorubicin derivatives against the mouse P388 tumor is directly proportional to RNA polymerase inhibition and inversely proportional to the rate of dissociation of the DNA complex. It is concluded that the biological efficacy of drugs which act at the replicative and transcriptional level may be estimated by the more rapid in vitro techniques provided that problems of permeability, solubility, stability, etc., in vivo are not encountered.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (1976) studied Mouse P388 tumor. Daunorubicin and its peptide derivatives was evaluated on Biological activity against mouse P388 tumor, RNA polymerase inhibition, and rate of dissociation of the DNA complex. The biological activity of daunorubicin derivatives against mouse P388 tumors is directly proportional to RNA polymerase inhibition and inversely proportional to DNA complex dissociation rate.
Synapse has enriched 10 related papers. Consider them for comparative context: